福元医药(601089) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 819,176,868.99, representing a year-on-year increase of 9.56%[5] - The net profit attributable to shareholders for the same period was CNY 113,705,518.99, reflecting a growth of 32.85% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 110,453,764.60, which is an increase of 38.66% year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.24, unchanged from the previous year[6] - The company's net profit for Q1 2023 reached CNY 115,180,784.67, a 34.0% increase compared to CNY 85,993,898.93 in Q1 2022[22] - Operating profit for Q1 2023 was CNY 128,371,945.32, representing a 34.5% increase from CNY 95,402,037.07 in Q1 2022[21] - Total revenue from sales and services amounted to CNY 768,393,348.37, an increase from CNY 698,299,027.48 in Q1 2022[26] - The company reported a total comprehensive income of CNY 115,180,784.67, compared to CNY 85,993,898.93 in the previous year[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,389,551,999.81, an increase of 1.57% from the end of the previous year[6] - The company's cash and cash equivalents amounted to RMB 2,234,007,135.50 as of March 31, 2023, compared to RMB 2,541,250,325.65 at the end of the previous period[16] - Total assets increased to RMB 4,389,551,999.81 as of March 31, 2023, from RMB 4,321,559,033.18 in the previous period, marking a growth of 1.57%[17] - Total liabilities decreased to RMB 1,096,041,312.29 from RMB 1,143,012,517.50, indicating a reduction of 4.12%[18] - The company's equity attributable to shareholders rose to RMB 3,287,522,769.50, up from RMB 3,174,033,863.34, reflecting an increase of 3.57%[18] Cash Flow - The net cash flow from operating activities was CNY 82,973,037.29, showing a decrease of 3.42% compared to the same period last year[5] - Cash flow from operating activities generated CNY 82,973,037.29, slightly down from CNY 85,907,088.90 in the same period last year[26] - The cash and cash equivalents at the end of Q1 2023 were CNY 2,233,696,135.50, down from CNY 2,540,939,325.65 at the beginning of the quarter[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,242[12] - The top shareholder, Xinheng Holdings Group Co., Ltd., held 176,316,354 shares, accounting for 36.7% of the total shares[12] Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 697,038,640.20, up from RMB 654,296,998.45 in Q1 2022, reflecting a year-over-year increase of 6.55%[20] - The company’s total operating expenses increased to CNY 726,393,620.19, up from CNY 626,208,958.59 in the previous year[26] - Research and development expenses increased to CNY 70,612,425.92, up 42.3% from CNY 49,602,481.80 in the previous year[21] - The company incurred financial expenses of CNY -13,068,037.21, compared to CNY -382,589.45 in Q1 2022[21] Market Strategy - The company is focusing on expanding its market presence and enhancing product development strategies in the upcoming quarters[20] Miscellaneous - The weighted average return on equity decreased by 3.30 percentage points to 3.52%[6] - Inventory levels were reported at RMB 340,817,417.24, slightly up from RMB 339,097,725.33, indicating a marginal increase of 0.51%[16] - There are no significant changes in the shareholder structure or related party transactions reported during this period[16] - The company reported non-recurring gains of CNY 3,251,754.39 for the quarter[9] - The company reported a net profit margin improvement, with net profit figures to be detailed in the full report[20]